When will Daprodustat enter medical insurance and will be reimbursed?

The original drug of daprodustat (Daprodustat) has not yet been launched in the Chinese market and has not been included in the scope of medical insurance. Therefore, specific information on its pricing and reimbursement is unclear. Nonetheless, as the drug is promoted in multiple markets around the world, it is likely to gradually gain attention and recognition in the Chinese market in the future, especially in the field of chronic kidney disease (CKD) treatment.

Globally, dapoxostat has been approved by the US FDA and became the first oral treatment for anemia caused by chronic kidney disease in dialysis patients in February 2023. However, in the Chinese market, although daprostat has broad clinical application prospects, it is currently not included in the medical insurance system due to its high price and the fact that the drug has not yet been officially launched in the country. This means that patients may need to pay for the drug out of pocket if they wish to use it, which may result in a greater financial burden for many patients.

With the approval of daprostat in Japan, the United States and other markets, pharmaceutical companies may seek marketing approval in China in the next few months or years, and may cooperate with domestic drug regulatory agencies to promote its early inclusion in the medical insurance directory. If the drug enters medical insurance, it may greatly reduce the cost of treatment for patients, allowing more chronic kidney disease patients in need to benefit.

In addition, as daprostat is promoted in the global market, more and more generic drug companies may begin to produce similar drugs in the future, which may depress drug prices to a certain extent. Patients will be able to obtain the drug through more channels, reducing the financial pressure of treating anemia.

Currently, the reimbursement status of daprostat depends on the medical insurance policies and drug approval processes of each country. In some developed countries, once a drug is approved, it is usually included in the medical insurance system relatively quickly, thus ensuring that a wide range of patients can receive treatment.

References: https://en.wikipedia.org/wiki/Daprodustat